Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): A single-centre, single-arm, phase II trial

被引：0
|
作者：
Liu, Z. [1 ]
Liu, M. [1 ]
Xu, J. [1 ]
Fu, H. [1 ]
Zhu, D. [1 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1827
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1735P
引用
收藏
页码：S1038 / S1038
页数：1
相关论文
共 50 条
  • [1] Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial
    Xu, Q.
    Chen, C.
    Huang, Z.
    Lin, Y.
    Liu, J.
    Li, L.
    Li, Z.
    Pan, J.
    Chen, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S752 - S753
  • [2] Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
    Xu, Qin
    Chen, Chuanben
    Sun, Yang
    Huang, Zhangzhou
    Lin, Yibin
    Liu, Jing
    Li, Li
    Li, Zirong
    Pan, Junping
    Chen, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [4] Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
    Wilky, Breelyn A.
    Trucco, Matte M.
    Subhawong, Ty K.
    Florou, Vaia
    Park, Wungki
    Kwon, Deukwoo
    Wieder, Eric D.
    Kolonias, Despina
    Rosenberg, Andrew E.
    Kerr, Darcy A.
    Sfakianaki, E. Rosyni
    Foley, Mark
    Merchan, Jaime R.
    Komanduri, Krishna, V
    Trent, Jonathan C.
    LANCET ONCOLOGY, 2019, 20 (06): : 837 - 848
  • [5] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
    Tian, Zhichao
    Dong, Shuping
    Zuo, Wenli
    Li, Po
    Zhang, Fan
    Gao, Shilei
    Yang, Yonghao
    Li, Chao
    Zhang, Peng
    Wang, Xin
    Wang, Jiaqiang
    Yao, Weitao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study
    Liu, Chao
    Jia, Qi
    Wei, Haifeng
    Yang, Xinghai
    Liu, Tielong
    Zhao, Jian
    Ling, Yan
    Wang, Chenguang
    Yu, Hongyu
    Li, Zhenxi
    Jiao, Jian
    Wu, Zhipeng
    Yang, Cheng
    Xiao, Jianru
    LANCET ONCOLOGY, 2020, 21 (09): : 1244 - 1252
  • [8] Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study
    Chen, L. K.
    Chen, J.
    Li, M. C.
    Yu, H.
    Zhang, B. S.
    Hou, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S48 - S49
  • [9] Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
    Fan, Y.
    Chen, K.
    Xu, Y.
    Huang, Z.
    Hong, W.
    Li, H.
    Xie, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S352 - S352
  • [10] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Shi, Jianxiang
    Su, Chang
    Li, Qinglong
    Su, Xiaoxing
    Chi, Huabin
    Lu, Xu
    Jiang, Guozhong
    Chen, Renyin
    Han, Jinming
    Jiang, Miao
    Qiao, Shishi
    Liu, Jingjing
    Song, Min
    Song, Lijie
    Du, Yabing
    Chang, Zhiwei
    Wang, Meng
    Dong, Meilian
    Zhong, Yali
    Yu, Pu
    Zhang, Xiaojian
    Zong, Hong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658
12345